RICHARD A. GRAHAM - 30 Oct 2023 Form 4 Insider Report for Theravance Biopharma, Inc. (TBPH)

Role: SVP, RESEARCH & DEVELOPMENT
Signature: /s/ Brett A. Grimaud, Attorney-in-Fact
Issuer symbol: TBPH
Transactions as of: 30 Oct 2023
Net transactions value: $0
Form type: 4
Filing time: 01 Nov 2023, 18:35:45 UTC
Previous filing: 18 Oct 2023
Next filing: 16 Nov 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TBPH	Ordinary Shares	Award	$0	+15,000	+4.5%	$0.000000	349,321	30 Oct 2023	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On March 1, 2023 the reporting person was granted a performance restricted stock unit award that vests based on the achievement of a performance condition by December 31, 2023 and continued employment. On October 30, 2023 the performance conditions were achieved. As a result 50% of the restricted stock units will vest on November 20, 2023 and the remaining 50% of the restricted stock units will vest on November 20, 2024, subject to the reporting person's continued service.

Content

On March 1, 2023 the reporting person was granted a performance restricted stock unit award that vests based on the achievement of a performance condition by December 31, 2023 and continued employment. On October 30, 2023 the performance conditions were achieved. As a result 50% of the restricted stock units will vest on November 20, 2023 and the remaining 50% of the restricted stock units will vest on November 20, 2024, subject to the reporting person's continued service.